Irinotecan HydrochlorideThird Party Manufacturing in India

Irinotecan is a semisynthetic derivative of camptothecin that functions as a potent topoisomerase I inhibitor. It acts as a prodrug that undergoes hydrolysis by carboxylesterase enzymes in the liver and tumor tissues to form its active metabolite SN-38, which is approximately 1,000 times more potent than the parent compound. Both irinotecan and SN-38 bind to the topoisomerase I-DNA complex, stabilizing it and preventing the religation of single-strand breaks in DNA. During DNA replication, the advancing replication fork collides with this stabilized complex, converting the single-strand breaks into lethal double-strand breaks. This collision triggers replication arrest and ultimately leads to apoptotic cell death. The cytotoxicity of irinotecan is S-phase specific, meaning it primarily affects cells that are actively synthesizing DNA. SN-38 is further metabolized by UDP-glucuronosyltransferase 1A1 (UGT1A1) to an inactive glucuronide conjugate, making genetic variations in UGT1A1 a significant factor in drug clearance and toxicity risk. Irinotecan also exhibits acetylcholinesterase inhibitory activity, which is responsible for its acute cholinergic side effects.

Therapeutic Uses

Irinotecan Hydrochloride is prescribed for the treatment of:

• Metastatic Colorectal Cancer: As first-line therapy in combination with 5-fluorouracil and leucovorin (FOLFIRI regimen) for patients with metastatic carcinoma of the colon or rectum.
• Second-Line Colorectal Cancer: As a single agent for patients whose disease has recurred or progressed following initial fluorouracil-based therapy.
• Pancreatic Adenocarcinoma: Nanoliposomal irinotecan in combination with 5-fluorouracil and leucovorin for metastatic pancreatic cancer after disease progression following gemcitabine-based therapy.
• Small-Cell Lung Cancer: Used in combination with cisplatin as an alternative to etoposide-based regimens.
• Ovarian Cancer: In combination with cisplatin for recurrent or refractory disease, with reported response rates of 20% to 25% in clinical trials.

Why Manufacturers Choose Irinotecan Hydrochloride

Irinotecan is a high-value oncology drug with established demand across global markets. Its inclusion in the WHO Essential Medicines List and its role as a backbone agent in multiple colorectal and pancreatic cancer regimens ensure consistent clinical demand. The drug is available in both liquid injectable and lyophilized powder forms, offering manufacturing flexibility. India is a major supplier of irinotecan API and injectable formulations to regulated markets including the US, EU, and semi-regulated markets.

This makes Irinotecan Hydrochloride a strategically important molecule for third party manufacturing in India, with growing demand from both domestic cancer care centers and export-oriented pharmaceutical companies.